-
@ Yahoo! Finance - by layer3.news
2025-05-07 07:15:24
nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r
✍️ Vertex Pharmaceuticals missed quarterly estimates due to lower-than-expected sales of its cystic fibrosis drug Trikafta, despite raising the lower end of its revenue forecast.
👉 Vertex Pharmaceuticals missed quarterly estimates due to lower-than-expected sales of its cystic fibrosis drug Trikafta
👉 The company raised the lower end of its revenue forecast, driven by growth from its newer CF drugs and acute pain drug Journavx
👉 Sales of Trikafta rose 2% to $2.53 billion, but missed analysts' average expectation of $2.58 billion
👉 Vertex reported a profit of $4.06 per share on an adjusted basis, compared to analysts' expectations of a profit of $4.32 per share
#ChristySanthosh #EvanSeigerman #SriparnaRoy #MohammedSafiShamsi #Bengaluru #business
nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpq5aplt05jhvv3au0kldxlj7g24g8y3g96dhxuw3prc2xmszarfuvq7slm0n